Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024 at 13:20 PM EST
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion.
